Patent ID: 8030359

Claim:
A pharmaceutical composition comprising: (a) a CETP inhibiting compound having formula Ii, or a pharmaceutically acceptable salt thereof: wherein R 1 is selected from the group consisting of H and —C 1 -C 2 alkyl; R 7 is selected from the group consisting of Cl and —CF 3 , Each R b is independently selected from the group consisting of —C 1 -C 3 alkyl, —OCH 3 , and F; Each R c is independently selected from the group consisting of halogen, —CH 3 —CF 3 , and —CN; q is 2 or 3; and t is an integer from 0-2; (b) a concentration-enhancing polymer selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate (HPMCAS), hydroxypropyl methyl cellulose phthalate (HPMCP), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), methyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, polyvinylpyrrolidinone, and polyvinylpyrrolidinone-polyvinylacetate copolymers; and (c) optionally one or more surfactants selected from the group consisting of sodium dodecyl sulfate and one or more nonionic surfactants selected from (a) sorbitan fatty acid esters, (b) polyoxyethylene sorbitan fatty acid esters, (c) polyoxyethylene castor oils, (d) polyoxyethylene hydrogenated castor oils, and (e) vitamin E TPGS; and mixtures thereof.